Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.

An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.

MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.

Blueprint looks to a next-gen Ayvakit, while Cogent challenges with a molecule acquired from Daiichi Sankyo.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.